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ABSTRACT: 
Currently genome-wide association studies (GWAS) and fine-mapping efforts 
have identified over 100 prostate cancer (PrCa) susceptibility loci. We meta-
analyzed genotype data from a custom high-density array of 46,939 PrCa cases 
and 27,910 controls of European ancestry with previously genotyped data of 
32,255 PrCa cases and 33,202 controls of European ancestry. Our analysis 
identified 62 novel loci associated (P<5.0x10-8) with PrCa, and a locus significantly 
associated with early-onset PrCa (≤ 55 years). Our findings include missense 
variants rs1800057 (OR=1.16; P=8.2x10-9; G>C [Pro1054Arg]) in ATM and 
rs2066827 (OR=1.06; P=2.3x10-9; T>G [Val109Gly]) in CDKN1B. The combination of 
all loci captures 28.4% of the PrCa familial relative risk and a polygenic risk score 
confers an elevated PrCa risk for men in the 90-99%-ile (RR=2.69; 95%CI: 2.55-
2.82) and 1%-ile (RR=5.71; 95%CI: 5.04-6.48) risk stratum compared to the 
population average. These findings improve risk prediction, enhance fine-
mapping, and provide insight into the underlying biology of PrCa1. 
 
MAIN TEXT: 
Although prostate cancer (PrCa) is the most common non-cutaneous cancer among 
men in the Western world and 1 in 7 men will be diagnosed during their lifetime2, very 
few modifiable risk factors have been established3. Epidemiological studies have 
identified age, a positive family history and race/ethnicity as the most prominent risk 
factors for PrCa4-7. PrCa incidence is highest among men of African ancestry, followed 
by men of European and Asian ancestry. These ancestral differences of PrCa risk, in 
conjunction with studies demonstrating the influence of family history8,9, highlight the 
contribution of genetics in PrCa etiology10. Our previous work, utilizing a multiplicative 
model, estimated over 1,800 common single nucleotide polymorphisms (SNPs) 
independently contribute to PrCa risk among populations of European ancestry11. 
Genome-wide association studies (GWAS) have reported over 100 of these PrCa 
variants across multi-ethnic populations, with the vast majority being identified in 
populations of European ancestry12-29.  
 
To facilitate additional novel discovery of PrCa genetic risk factors we developed a 
custom high-density genotyping array, the OncoArray, including a 260K SNP backbone 
designed to adequately tag most common genetic variants (MAF>5% in Europeans), 
and 310K SNPs from the meta-analyses of five cancers (breast, colorectal, lung, 
ovarian, and prostate)30. Approximately 80,000 PrCa-specific markers derived from our 
previous multi-ethnic meta-analysis12 (including populations of European, African 
American, Japanese, and Latino ancestry), fine-mapping of known PrCa loci, and 
candidate SNPs nominated by study collaborators were included on the OncoArray. We 
assembled a new PrCa sample series from 52 studies to genotype with the OncoArray 
(Supplementary Tables 1 & 2). After applying rigorous quality control criteria and 
removing overlapping samples from previous studies, our OncoArray sample yielded 
46,939 PrCa cases and 27,910 controls without a known diagnosis of PrCa of European 
ancestry for analysis (see Online Methods, Supplementary Table 3). Genotypes were 
phased and imputed to the cosmopolitan panel of the 1000 Genomes Project (1KGP; 
2014 June release) using SHAPEIT31 and IMPUTEv232 software (Online Methods, 
Supplementary Table 3). We performed a fixed-effects meta-analysis combining the 
summary statistics from our OncoArray analysis, and seven previous PrCa GWAS or 
high-density SNP panels of European ancestry imputed to 1KGP. The final meta-
analysis included 79,194 PrCa cases and 61,112 controls without a known diagnosis of 
PrCa (Figure 1).  
 
Study- and consortia-specific meta-analyses were performed to identify novel PrCa loci. 
We established a P-value threshold of 5.0x10-8 to determine genome-wide significance. 
Our large sample size enabled several stratified meta-analyses focusing on key clinical 
and biological parameters (Online Methods, Supplementary Tables 4 & 5). All 
analyses used a likelihood ratio test to minimize bias from rare variants and a logistic 
regression framework was used for all analyses, except for Gleason score where linear 
regression was utilized. The genotype dosages were incorporated in an allelic genetic 
model. The average λ1000, an inflation statistic calibrated to a sample size of 1000 cases 
and 1000 controls33, across the eight GWAS studies was 1.02 (range: 0.98-1.09) and 
1.00 for the overall meta-analysis (Supplementary Table 6). Our novel findings 
excluded variants within defined fine-mapped regions of previously reported PrCa loci 
(Supplementary Table 7). 
 
After the exclusion of all known susceptibility regions (fine-mapping coordinates provided 
in Supplementary Table 7 & Supplementary Note) we identified 64 loci associated 
with overall PrCa susceptibility and one with early-onset (P<5.0x10-8) in the meta-
analysis (Supplementary Figure 1), where 53 were imputed and 12 were genotyped 
using the OncoArray . The cluster plots for the genotyped makers are presented in 
Supplementary Figure 2. Although a majority of the imputed markers were of high 
quality with an average imputed r2 greater than 0.80 for 61 of the 65 loci across all 
contributing GWAS (Supplementary Table 8), we closely examined four variants with a 
poor imputation quality score (r2 <0.80) in the OncoArray samples by inspecting linkage 
disequilibrium (LD) plots including only genotyped SNPs from the OncoArray and 
performing an imputation quality control assessment (Online Methods). After reviewing 
the LD plots and the imputation QC, we determined loci rs6602880 and rs144166867 
are likely false positives due to imputation artifacts (Supplementary Figure 3; 
Supplementary Table 9). Overall, we identified 62 novel loci associated with overall 
PrCa risk and one novel loci associated with early-onset (Table 1). The consortia 
specific associations were consistent across the eight contributing GWAS studies 
(Supplementary Table 10).  
 
We performed several stratified analyses defined by clinical and population parameters. 
We detected a novel variant, rs138004030, significantly associated with early-onset 
disease (Table 1), but only nominally significant for overall PrCa risk (P=0.02). In 
addition, we detected four markers significantly associated (P<5x10-8) with advanced 
PrCa and two markers associated with early-onset PrCa (Supplementary Table 11). 
However, the case-only analyses of these markers indicated marginal statistical 
significance (P<1.0x10-3). Additionally, these markers were in LD with nearby index 
markers associated with overall PrCa and not significantly associated with overall 
aggressive disease after adjusting for the index marker (Supplementary Table 11). A 
similar association pattern was observed for rs111599055, which was in LD with marker 
rs7295014 (r2=0.54) associated with overall disease. The early-onset marker 
rs77777548 is independent of novel and known PrCa loci. However, the marker is 
relatively rare (EAF<0.02), indicated as monomorphic in 1KGP, and has a moderate 
imputation quality score (average r2=0.57) hence we did not include it in further 
analyses.  
 
Among the 63 novel associations, 38 variants are located within gene-rich regions 
(Supplementary Table 12): intronic (32 SNPs), missense (4 SNPs), and 3’-UTR (2 
SNPs). eQTL analyses of the TCGA database identified statistically significant 
associations (P<0.05; Supplementary Table 12) in normal PrCa tissue for 17 of the 
novel associations, including both 3’UTR SNPs and 11 of the 32 intronic SNPs. Cis 
eQTL associations were identified for 3’UTR variant rs1048169 with HAUS6 (3’UTR) and 
intronic variants rs182314334 with MBNL1, rs4976790 with COL23A1, rs9469899 with 
UHRF1BP1, rs878987 with B3GAT1, rs11629412 with PAX9, and rs11666569 with 
MYO9B. The eQTL associations are consistent with the observed PrCa-SNP 
associations, given we assessed colocalization between the GWAS and eQTL SNPs. 
The TCGA data analysis failed to identify an eQTL association with any of the four 
missense SNPs.  
 
We assessed the association of our newly discovered loci with prostate-specific antigen 
(PSA) levels using a series of disease-free controls (N=9,090; see Online Methods). 
Among the 48 available loci we observed a significant association for rs8093601 
(P=5.0x10-4; Supplementary Table 13) after correcting for multiple testing 
(P=0.05/48=1.0x10-3). This marker lies near MBD2, methyl-CpG binding domain protein 
2, and has not been previously associated with either PrCa risk or PSA levels. The effect 
estimates of PrCa clinical features and overall PrCa did not differ (Supplementary 
Table 14). LD plots incorporating several functional annotation features for each of the 
63 novel markers is presented in Supplementary Figure 4. 
 
Several strong candidate genes were identified among the PrCa susceptibility loci, 
including ATM, a key gene within the DNA damage response pathway, in which 
truncating variants contribute towards PrCa susceptibility and progression, particularly 
aggressive PrCa34,35. The index variant within this region is the missense variant 
rs1800057, exerting a modest increased risk of PrCa (OR=1.16; P=8.15x10-9; G>C 
[Pro1054Arg]; Figure 2, Panel A). Although rs1800057 is designated ‘benign’ by ClinVar 
(http://www.ncbi.nlm.nih.gov/clinvar/), it was previously suggested to be associated with 
a two-fold increased risk of early-onset PrCa in a small clinical series and was 
unassociated with morbidity following treatment36. In addition to the ATM region, we 
identified missense variants in three separate loci: rs2066827 within the cyclin-
dependent kinase inhibitor CDKN1B, which controls cell cycle progression; rs33984059 
within the transcription factor RFX7; and rs2277283 within INCENP, which encodes a 
centromere-interacting protein.  
 
rs1048169 at 9p22 is located in the 3’UTR of HAUS6 (Figure 2, Panel B), a gene that 
encodes a subunit of augmin, a protein complex required for proper microtubule 
formation and chromosome segregation during cell division37. rs1048169 is also an 
eQTL for HAUS6 expression. Interestingly, an additional lead SNP identified in this 
study, rs11666569 at 19p13, was an eQTL for two genes including HAUS8, which is 
another member of the augmin complex. These discoveries may implicate a potential 
role for augmin in PrCa susceptibility. 
 
Variant rs7968403 (OR=1.06; P=3.38x10-12; Figure 2, Panel C) is situated within the first 
intron of RASSF3. Members of the Ras association domain family (RASSF) are putative 
tumor suppressors implicated in a range of biological processes38. RASSF3 is 
ubiquitously expressed across tissue types and has been observed to arrest the cell 
cycle in the G1 phase and induce apoptosis through the p53 pathway39. A previously 
identified PrCa risk locus, ~100kb away, within the RASSF6 family member was 
previously identified11. However, rs7968403 was also an eQTL for the distant WIF1 
(WNT inhibitory factor 1) gene (Figure 2, Panel C). WIF1 inhibits Wnt signaling and is 
frequently down regulated in PrCa40, whilst aberrant activation of Wnt signaling is 
common in many solid tumor types. Restoration of WIF1 expression has also been 
demonstrated to decrease cell motility and invasiveness in a metastatic PrCa cell-line 
and reduce tumor growth in a mouse xenograft model41. Both RASSF3 and WIF1 
therefore represent plausible mechanisms for the modulation of PrCa risk at this locus. 
 
rs28441558 at 17p13 is the lead variant for a cluster of highly correlated SNPs centered 
on the CHD3 gene (Figure 2, Panel D). CHD3 is an ATPase that forms a component of 
the NuRD (nucleosome remodeling and deacetylase) histone deacetylase complex, 
involved in chromatin remodeling. NuRD plays an important role in regulating gene 
expression, both as a silencer and activator of transcription, in addition to maintenance 
of genomic integrity and the DNA damage response42. Alterations to NuRD function 
have been implicated in several cancer types in a highly complex manner43,44. 
Additionally however, rs28441558 was observed to be an eQTL for three genes; 
LOC284023, a currently uncharacterized non-coding RNA transcript, GUCY2D, a 
guanylate cyclase enzyme expressed predominantly in the retina and ALOX15B, a 
member of the lipoxygenase family of enzymes that produce fatty acid hyperoxides. 
Although CHD3 appears to represent the most biologically plausible candidate gene for 
this locus, we cannot exclude a role for any of these genes. 
 
Our pathway analysis based on mapping each SNP to the nearest gene (see Online 
Methods) using the meta-analysis summary association statistic identified several 
pathways implicated in PrCa susceptibility. The top 53 pathways detected (enrichment 
score, ES>0.50) are provided (Supplementary Table 15). The most significant pathway 
detected was PD-1 signaling (ID: 389948), ES=0.74, as defined by the REACTOME 
database (Supplementary Figure 5). This pathway is intriguing given the therapeutic 
potential of several checkpoint inhibitors focusing on the PD-1 signaling pathway to 
enhance immune responses45.   
 
In summary, we have identified 63 novel PrCa susceptibility variants, including strong 
candidate loci highlighting the DNA repair and cell cycle pathways. Previous studies 
likely overestimated the effect estimates of PrCa loci due to the “winner’s curse”, thus 
yielding a biased FRR and polygenic risk score (PRS). Here, we apply a weighted 
Bayesian correction approach and demonstrate our large sample size minimizes the 
“winner’s curse” bias (Online Methods; Supplementary Figure 6)46. We applied the 
beta estimates calculated in our overall meta-analysis to the OncoArray sample set to 
calculate the FRR and PRS risk models (Supplementary Table 16). Our prediction 
models included 85 previously reported PrCa loci replicating in our overall meta-analysis 
and our 62 novel loci associated with overall PrCa risk. Assuming a familial risk estimate 
of 2.5 for PrCa47,48, we demonstrate our 147 loci captures 28.4% of the FRR 
(Supplementary Table 17). The newly 62 identified PrCa loci increase the FRR by 
4.4%. On the assumption of a log-additive model, the estimated RR for PrCa relative to 
men in the 25-75% PRS percentile (baseline group) was 5.71 (95%CI: 5.04-6.48) for 
men in the top 1% of the polygenic risk score (PRS) distribution and 2.69 (95%CI: 2.55-
2.82) for individuals in the 90-99%-ile of the PRS (Table 2). The PRS score was 
positively associated with overall PrCa compared to all controls (OR=1.86; 95%CI: 1.83-
1.89; Supplementary Table 18). Our novel associations highlight several biological 
pathways that suggest further investigation is warranted. The increased PRS can be 
used to improve the identification of men at high risk of PrCa and therefore inform PSA 
guidelines for screening and management to reduce the burden of over testing.  
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FIGURE LEGENDS: 
Figure 1. ELLIPSE/PRACTICAL study overview of prostate cancer (PrCa) GWAS 
meta-analysis. The top section describes the PrCa GWAS meta-analysis published in 
2014 (AA Olama et al, Nature Genetics 201412) where 23 novel variants were identified. 
The current PrCa GWAS meta-analysis incorporates an additional 46,939 PrCa cases 
and 27,910 controls independent of the meta-analyses. The current meta-analysis 
discovered 62 novel variants associated with overall PrCa and 1 novel variant 
associated with early-onset PrCa. 
 
 
Figure 2. Locus Explorer plots depicting the statistical association with PrCa and 
biological context of variants from four of the novel prostate cancer loci identified 
(N=74,849 biologically independent samples). For each panel (a-d), top panels depict 
Manhattan plots of variant -log10 P values (y-axis), with the index SNP labeled. Variants 
that were directly genotyped by the OncoArray are represented as triangles and imputed 
variants are represented as circles. Variants in linkage disequilibrium with the index SNP 
are denoted by color (red = r2 >0.8, orange = r2 0.6-0.8, yellow = r2 0.4-0.6, green = r2 
0.2-0.4, blue = r2 ≤0.2). Middle panels depict the relative locations of selected biological 
annotations; histone marks within 7 cell lines from the ENCODE project; genes for which 
the index SNP is an eQTL in the TCGA prostate adenocarcinoma dataset; chromatin 
state annotation by ChromHMM in PrEC cells; conserved elements within the genome 
and DNAseI hypersensitivity sites in ENCODE prostate cell lines. The lower panel 
denotes the position of genes within the region, with genes on the positive and negative 
strands marked in green and purple, respectively. The horizontal axis represents 
genomic co-ordinates in the hg19 reference genome. (a) rs1800057 (chr11:107643000-
108644000) - The index variant is a non-synonymous SNP in the ATM gene. (b) 
rs1048160 (chr9:18556000-19557000) - The index variant is located within the 3’UTR of 
the HAUS6 gene and is an eQTL for HAUS6. (c) rs7968403 (chr12:64513000-
65514000) - The signal is centered on the RASSF3 gene, with the index variant located 
within the first intron. This SNP is also situated within a region annotated for multiple 
regulatory markers and is an eQTL for the more distant WIF1 gene. (d) rs28441558 
(chr17:7303000-8304000) - The signal implicates a cluster of highly correlated variants 
centered upon the CHD3 gene. The index SNP is also an eQTL for three other more 
distantly located genes.  
  
  
  
Table 1. Prostate cancer OncoArray and GWAS meta-analysis for 63 novel regions. 
          SNP Reference RAF a Band Position Nearest Gene Alleles b RAF c OR d 95% CI e P-value f 
Novel loci associated with overall prostate cancer 
rs56391074 0.329 1p22.3 88210715 RP11-60A14.1 AT/A 0.38 1.05 1.03-1.06 1.7E-08 
rs34579442 0.316 1q21.3 153899900 DENND4B C/CT 0.34 1.07 1.05-1.09 4.5E-14 
rs62106670 0.400 2p25.1 8597123 AC011747.3 T/C 0.38 1.05 1.04-1.07 7.1E-09 
rs74702681 0.024 2p14 66652885 MEIS1-AS3 T/C 0.02 1.17 1.11-1.23 2.0E-09 
rs11691517 0.750 2q13 111893096 BCL2L11 T/G 0.74 1.07 1.05-1.08 3.5E-12 
rs34925593 0.481 2q31.1 174234547 CDCA7 C/T 0.48 1.05 1.03-1.07 2.8E-08 
rs59308963 0.726 2q33.1 202123479 CASP8 T/TATTCTGTC 0.73 1.05 1.03-1.07 2.4E-08 
rs1283104 0.407 3q13.12 106962521 DUBR G/C 0.38 1.05 1.03-1.07 8.8E-09 
rs182314334 0.888 3q25.1 152004202 MBNL1 T/C 0.90 1.09 1.06-1.12 4.1E-11 
rs142436749 0.012 3q26.2 169093100 MECOM G/A 0.01 1.25 1.16-1.34 4.7E-09 
rs10793821 0.580 5q31.1 133836209 RNU6-456P T/C 0.57 1.05 1.04-1.07 5.4E-11 
rs76551843 0.991 5q35.1 169172133 DOCK2 A/G 0.99 1.31 1.19-1.44 1.7E-08 
rs4976790 0.096 5q35.3 177968915 COL23A1 T/G 0.11 1.08 1.05-1.10 6.7E-09 
rs12665339 0.148 6p21.33 30601232 ATAT1 G/A 0.17 1.06 1.04-1.08 5.6E-09 
rs9296068 0.645 6p21.32 32988695 HLA-DOA T/G 0.65 1.05 1.03-1.07 1.3E-08 
rs9469899 0.356 6p21.31 34793124 UHRF1BP1 A/G 0.36 1.05 1.03-1.07 5.3E-09 
rs4711748 0.232 6p21.1 43694598 RP1-261G23.5 T/C 0.23 1.05 1.03-1.07 3.4E-08 
rs527510716 0.251 7p22.3 1944537 MAD1L1 C/G 0.24 1.06 1.04-1.08 4.9E-08 
rs11452686 0.567 7p21.1 20414110 ITGB8 T/TA 0.56 1.05 1.03-1.07 7.8E-09 
rs17621345 0.758 7p14.1 40875192 SUGCT A/C 0.74 1.07 1.05-1.09 6.7E-14 
rs1048169 0.367 9p22.1 19055965 HAUS6 C/T 0.38 1.06 1.05-1.08 6.5E-14 
rs10122495 0.296 9p13.3 34049779 RN7SKP114 T/A 0.31 1.05 1.03-1.07 1.3E-08 
rs1182 0.258 9q34.11 132576060 TOR1A A/C 0.22 1.06 1.04-1.08 1.1E-09 
rs141536087 0.166 10p15.3 854691 LARP4B GCGCA/G 0.15 1.08 1.06-1.11 9.0E-13 
rs1935581 0.605 10q23.31 90195149 RNLS C/T 0.63 1.05 1.03-1.07 6.5E-09 
rs7094871 0.540 10q25.2 114712154 TCF7L2 G/C 0.54 1.04 1.03-1.06 4.8E-08 
rs1881502 0.193 11p15.5 1507512 MOB2 T/C 0.19 1.06 1.04-1.08 7.4E-09 
rs61890184g 0.088 11p15.4 7547587 PPFIBP2 A/G 0.12 1.07 1.05-1.10 6.6E-09 
rs547171081 0.468 11p11.2 47421962 RP11-750H9.5 CGG/C 0.47 1.05 1.03-1.07 3.4E-08 
rs2277283 0.300 11q12.3 61908440 INCENP C/T 0.31 1.06 1.04-1.08 3.0E-10 
rs12785905 0.051 11q13.2 66951965 KDM2A C/G 0.05 1.12 1.08-1.17 7.8E-09 
rs11290954 0.688 11q13.5 76260543 C11orf30 AC/A 0.68 1.06 1.05-1.08 7.4E-13 
rs1800057 0.031 11q22.3 108143456 ATM G/C 0.02 1.16 1.10-1.22 8.1E-09 
rs138466039 0.009 11q24.2 125054793 PKNOX2 T/C 0.01 1.32 1.22-1.44 2.0E-11 
rs878987 0.143 11q25 134266372 B3GAT1 G/A 0.15 1.07 1.04-1.09 4.8E-08 
rs2066827 0.757 12p13.1 12871099 CDKN1B T/G 0.76 1.06 1.04-1.08 2.3E-09 
rs10845938 0.554 12p13.1 14416918 RNU6-491P G/A 0.55 1.06 1.04-1.08 9.8E-13 
rs7968403 0.655 12q14.2 65012824 RASSF3 T/C 0.64 1.06 1.04-1.08 3.4E-12 
rs5799921 0.697 12q21.33 90160530 RNU6-148P GA/G 0.68 1.06 1.04-1.08 7.0E-12 
rs7295014 0.342 12q24.33 133067989 FBRSL1 G/A 0.35 1.05 1.04-1.07 9.5E-10 
rs1004030 0.581 14q11.2 23305649 MMP14 T/C 0.58 1.05 1.03-1.06 1.5E-08 
rs11629412 0.582 14q13.3 37138294 PAX9 C/G 0.58 1.06 1.04-1.08 2.3E-12 
rs4924487 0.836 15q15.1 40922915 CASC5 C/G 0.81 1.06 1.04-1.09 1.3E-08 
rs33984059 0.982 15q21.3 56385868 RFX7 A/G 0.98 1.19 1.12-1.27 1.1E-08 
rs112293876 0.280 15q22.31 66764641 MAP2K1 C/CA 0.29 1.06 1.04-1.08 3.5E-10 
rs11863709 0.945 16q21 57654576 GPR56 C/T 0.96 1.16 1.11-1.21 1.8E-11 
rs201158093 0.435 16q23.3 82178893 RP11-510J16.5 TAA/TA 0.44 1.05 1.03-1.07 9.1E-09 
rs28441558 0.050 17p13.1 7803118 CHD3 C/T 0.05 1.16 1.12-1.20 1.0E-16 
rs142444269 0.798 17q11.2 30098749 RP11-805L22.3 C/T 0.78 1.07 1.05-1.09 3.2E-10 
rs2680708 0.623 17q22 56456120 RNF43 G/A 0.61 1.05 1.03-1.06 1.6E-08 
rs8093601 0.459 18q21.2 51772473 MBD2 C/G 0.44 1.05 1.03-1.06 2.3E-08 
rs28607662 0.085 18q21.2 53230859 TCF4 C/T 0.10 1.08 1.05-1.11 2.8E-08 
rs12956892 0.300 18q21.32 56746315 OACYLP T/G 0.30 1.05 1.03-1.07 7.7E-09 
rs533722308 0.390 18q21.33 60961193 BCL2 CT/C 0.42 1.05 1.03-1.07 1.2E-08 
rs10460109 0.414 18q22.3 73036165 TSHZ1 T/C 0.42 1.05 1.03-1.06 3.5E-08 
rs11666569 0.728 19p13.11 17214073 MYO9B C/T 0.71 1.05 1.03-1.07 8.2E-09 
rs118005503 0.912 19q12 32167803 THEG5 G/C 0.91 1.09 1.06-1.13 7.3E-09 
rs61088131 0.848 19q13.2 42700947 POU2F2 T/C 0.82 1.06 1.04-1.09 8.8E-09 
rs11480453 0.641 20q11.21 31347512 DNMT3B C/CA 0.60 1.05 1.03-1.06 3.2E-08 
rs6091758 0.465 20q13.2 52455205 BCAS1 G/A 0.47 1.07 1.06-1.09 6.4E-18 
rs9625483 0.026 22q12.1 28888939 TTC28 A/G 0.03 1.14 1.09-1.20 2.4E-08 
rs17321482 0.873 23p22.2 11482634 ARHGAP6 C/T 0.87 1.07 1.05-1.09 2.1E-13 
Novel loci associated with early-onset 
rs138004030 0.920 6q27 170475879 LOC154449 G/A 0.91 1.27 1.17-1.38 2.9E-08 
                
 
 a Risk allele frequency - 1000 Genomes Project Europeans 
b Risk allele/Reference allele 
c Risk allele frequency 
d Odds ratio and confidence interval 
e Confidence interval 
f P-values are generated from a likelihood ratio test 
g Region previously reported by Wang et al (Nat Comm 2015), rs12791447; rs61890184-rs12791447 r2 (EUR)=0.41 
  
  
Table 2.  Polygenic Risk Score (PRS) estimation using 147 prostate cancer 
susceptibility variants. 
   Risk Category Percentiles a RR 95% CI 
<1% 0.15 0.11-0.20 
1-10% 0.35 0.32-0.37 
10-25% 0.54 0.51-0.57 
25-75% 1.00 (Baseline) 
 
75-90% 1.74 1.67-1.82 
90-99% 2.69 2.55-2.82 
≥99% 5.71 5.04-6.48 
a Polygenetic Risk Score (PRS) percentiles based on the cumulative score 
distributed among controls. The beta coefficients computed from the European 
overall meta-analysis was applied to determine the PRS risk among individuals in 
the OncoArray study. 
b Relative risk and 95% confidence intervals. 
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ONLINE METHODS: 
Study subjects 
A brief overview and study details for participating prostate cancer (PrCa) studies in 
the newly genotyped OncoArray project are provided in Supplementary Table 11 for 
men of European ancestry. All studies were approved by the appropriate ethics 
committees and informed consent was obtained from all participants. Supplementary 
Table 2 summarizes the PrCa sample series of the Elucidating Loci Involved in 
Prostate Cancer Susceptibility (ELLIPSE) consortia contributing both newly obtained 
genotyping data for the OncoArray and previous genome-wide association studies 
(GWAS). The majority of the studies contributing to the OncoArray were case-control 
studies primarily based in either the United States or Europe. In total 52 new studies 
provided core data on disease status, age at diagnosis (age at observation or 
questionnaire for controls), family history of PrCa, and clinical factors for cases (e.g. 
PSA at diagnosis, Gleason score, etc.) for 48,455 PrCa cases and 28,321 disease-
free controls. Previous GWAS contributed an additional 32,255 PrCa cases and 
33,202 disease-free controls of European ancestry for the overall meta-analysis1. 
Supplementary Table 3 provides quality control information by consortia (i.e. 
OncoArray project, UK GWAS, etc) for both samples and SNPs. After removing all 
overlapping samples the OncoArray contribution for newly genotyped samples was 
46,939 PrCa cases and 27,910 disease-free controls. 
Several strata-specific analyses were implemented to evaluate the impact of genetic 
variation in PrCa disease aggressiveness. Supplementary Table 4 describes the 
analysis title, outcome and reference groups, and the statistical model used. Several 
classification schemes (i.e. low aggressiveness, intermediate aggressiveness, etc.) 
were implemented to better assess the spectrum of genetic involvement. All 
classification schemes incorporated the diagnostic clinical features PSA, tumor stage 
and Gleason score. In order to compare to previous PrCa aggressive analyses1 by 
our research group, we included the ‘Advanced (plus death due to PrCa)’ 
classification. Contributing study groups missing clinical features were excluded 
(Supplementary Table 2). Individuals with missing or granular clinical information 
were excluded. The strata-specific sample sizes by PrCa GWAS consortium are 
provided in Supplementary Table 5. Furthermore we analysed Gleason score as a 
continuous variable. 
OncoArray SNP selection 
The NCI Genetic Associations and Mechanisms in Oncology (GAME-ON) 
consortia (http://epi.grants.cancer.gov/gameon/) provided SNPs to be included 
on the Illumina OncoArray. Approximately 50% of the OncoArray was a 
compilation of SNP lists by the GAME-ON disease consortia of cancer (breast, 
colorectal, lung, ovarian, and prostate), a common set of variants for common 
risk regions, other related traits (i.e. BMI, age at menarche, etc), 
pharmacogenetics, and candidates2. The remaining content of the OncoArray 
was selected as a “GWAS backbone” (Illumina HumanCore), which aimed to 
provide high coverage for the majority of common variants through imputation. 
Approximately 79k SNPs were selected specifically for their relevance to PrCa, 
based on prior evidence of association with overall or subtype-specific disease, 
fine-mapping of known PrCa regions, and candidate submissions (i.e. survival, 
exome sequencing, etc). In order to maximize efficiency of the array, cancer-
specific candidate lists were merged to remove redundant genetc variation3. 
Genotype calling and quality control 
Details of the genotype calling and quality control (QC) for the iCOGS and 
GWAS are described elsewhere4-20. 
Of the 568,712 variants selected for genotyping on OncoArray, 533,631 were 
successfully manufactured on the array (including 778 duplicate probes). 
OncoArray genotyping of ELLIPSE studies was conducted at five sites 
(Cambridge [UK], CIDR, Copenhagen, USC, NCI). Details of the genotyping 
calling for the OncoArray are described in more detail elsewhere3. Briefly, we 
developed a single calling pipeline that was applied to more than 500,000 
samples across the GAME-ON consortia. An initial cluster file was generated 
using 56,284 samples selected from all major genotyping centers and ethnicities, 
using the Gentrain2 algorithm. Variants likely to have problematic clusters were 
selected for manual inspection using the following criteria: call rate below 99%, 
minor allele frequency (MAF) <0.001, poor Illumina intensity and clustering 
metrics, deviation from the MAF observed in the 1000 Genomes Project (1KGP) 
using the criterion: 
(|𝑝1−𝑝0|−0.01)
2
((𝑝1+𝑝0)(2−𝑝1−𝑝0))
> 𝐶 , where p0 and p1 are the minor 
frequencies in the 1KGP and OncoArray datasets, respectively, and C=0.008. 
This resulted in manual adjustment of the cluster file for 3,964 variants, and the 
exclusion of 16,526 variants. The final cluster file was then applied to the full 
dataset. 
Our quality control pipeline for ELLIPSE excluded SNPs with a call rate <95% by 
study, not in Hardy-Weinberg equilibrium (P<10-7 in controls, or P<10-12 in cases) 
or with concordance <98% among 11,260 duplicate pairs. In order to minimize 
imputation errors, we additionally excluded SNPs with a MAF<1% and a call rate 
<98% in any study, SNPs that could not be linked to the 1KGP reference, those 
with MAF for Europeans that differed from that for the 1KGP and a further 16,526 
SNPs where the cluster plot was judged to be not ideal. Of the 533,631 
manufactured SNPs on the OncoArray, we retained 498,417 SNPs among our 
samples of European ancestry following QC. 
We excluded duplicate samples and first-degree relatives within each study, 
duplicates across studies, samples with a call rate <95%, and samples with 
extreme heterozygosity (>4.9 standard deviations from the mean for the reported 
ethnicity). We excluded duplicated samples as well as first-degree relatives 
across the GWAS studies CAPS1, CAPS2, UK Stage 1, UK Stage 2, and 
iCOGS. Duplicate and first-degree related samples were assessed across the 
BPC3 and Pegasus GWAS studies as well. Ancestry was computed using a 
principal component analysis using 2,318 informative markers on a subset of 
~47,000 samples and projected onto the complete OncoArray dataset. The 
current analysis was restricted to men of European ancestry, defined as 
individuals with an estimated proportion of European ancestry >0.8, with 
reference to the HapMap populations, based on the first two principal 
components. Of the 78,182 samples genotyped (regardless of race/ethnicity), the 
final dataset consisted of 74,849 samples, of which 46,939 PrCa cases and 
27,910 disease-free controls (Supplementary Table 3) after excluding overlap 
samples, were meta-analysed with previous studies.  
Imputation 
Genotypes for ~70M SNPs were imputed for all samples using the October 2014 
(Phase 3) release of the 1KGP data as the reference panel. The OncoArray and 
GWAS datasets were imputed using a two-stage imputation approach, using 
SHAPEIT21 for phasing and IMPUTEv222 for imputation. The imputation was 
performed in 5Mb non-overlapping intervals. All subjects were split into subsets 
of ~10,000 samples, with subjects from the same group in the subset. We 
imputed genotypes for all SNPs that were polymorphic (MAF>0.1%) in European 
samples. We excluded data for all monomorphic SNPs and those with an 
imputation r2<0.3 leaving a total of 20,370,935 SNP across chromosomes 1-22 
and chromosome X. Of the SNPs imputed, 49.3% had a MAF<1%, 15.2% had a 
MAF ranging between 1-5%, and 35.5% had a MAF≥5%. 
 
Statistical analyses 
Per-allele odds ratios and standard errors were generated for the OncoArray and 
each GWAS, adjusting for principal components and study relevant covariates 
using logistic regression. The OncoArray and iCOGS analyses were additionally 
stratified by country and study, respectively. We used the first seven principal 
components in our analysis of individuals of European ancestry, as additional 
components did not further reduce inflation in the test statistics.  
 
Odds ratio (OR) estimates were derived using either SNPTEST 
(https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html) or an in-
house C++ program (Supplementary Table 3). OR estimates and standard 
errors were combined by a fixed effects inverse variance meta-analysis using 
METAL23.  All statistical tests conducted were two-sided. 
 
Our analyses included overall PrCa and several clinically relevant strata. These 
included: 1) high vs low aggressive PrCa; 2) high vs low/intermediate aggressive 
PrCa; 3) advanced vs non-advanced PrCa; 4) advanced PrCa vs controls; 5) 
early-onset PrCa (≤55 yrs) vs controls; and 6) Gleason score (Supplementary 
Tables 4 & 5). We defined low aggressive as tumor stage ≤T1 and Gleason ≤6 
and PSA <10 ng/mL, intermediate aggressive as tumor stage T2 or Gleason=7 or 
PSA 10-20 ng/mL, high aggressive as tumor stage T3/T4 or N1 or M1 or Gleason 
≥8 or PSA >20 ng/mL, and advanced as either metastatic disease, Gleason ≥8, 
PSA>100 or PrCa-related deaths (Supplementary Table 4). 
 
Definition of new hits 
To search for novel loci, we assessed all SNPs excluding those within a known 
PrCa locus, defined by current fine-mapping assessments (Supplementary 
Table 7). SNPs that were associated with disease risk at P<5x10-8 in the meta-
analysis (GWAS and OncoArray) were considered novel. The SNP with the 
lowest p-value in a region was considered the lead SNP. Imputation quality 
assessed by IMPUTE2 imputation r2 in the OncoArray dataset (Supplementary 
Table 8).  
 
For ten regions where the newly identified locus was near a previously known 
region, we reported a novel association if the pairwise r2 between the new and 
the previously known SNP was less than 0.2. For novel PrCa associations where 
the variant was imputed in the OncoArray study samples series and had an 
imputed quality score less than 0.70, we assessed the quality of the imputation 
by masking the variant in a subset of the 1KGP European sample and calculating 
the concordance following re-imputation in the remaining 1KGP samples. 
 
Reliability of Imputation 
Novel SNPs with an IMPUTE2 r2<0.80 among the OncoArray sample series 
(Supplementary Table 8) were flagged for further investigation to minimize the 
probability of a false positive. First, we examined linkage disequilibrium (LD) plots 
(http://locuszoom.org/) for poorly imputed SNPs (+/-500kb) including only 
genotyped SNPs within the region. The imputed index SNP was included in the 
plot to determine the strength of LD with nearby signals and assess a pattern of 
association. Furthermore, we performed an imputation experiment using the 
2,504 1KGP Phase 3 samples. We split this sample into two parts: a random 
sample of 259 individuals of European ancestry (excluding the Finnish) and a 
mixed-population reference panel of 2,245 individuals. The random sample of 
259 individuals of European ancestry was filtered to include only the genetic 
variants available from the OncoArray following QC. This ensured the same 
imputation input used in the overall imputation. The 259 individuals were imputed 
using 2,245 individuals as the reference panel. A 5 MB segment of the genome 
was selected based on the target SNP (+/- 250 MB). SHAPEIT2 was used for 
pre-phasing and IMPUTE2 for imputation. Customized imputation settings 
included an effect size of 20,000, allowance of large region imputation and a 
random seed of 12345. A weighted linear Kappa statistic was calculated to 
determine correlation of the imputation with the true genotypes. 
We evaluated four SNPs where the IMPUTE2 r2 was less than 0.80 in the 
OncoArray sample series: rs527510716 (Chr 7), rs6602880 (Chr 10), 
rs533722308 (Chr 18) and rs144166867 (Chr X). Supplementary Figure 3 
includes the LD plots for three of the poorly imputed SNPs. The variant 
rs144166867 (Chr X) could not be plotted given no genotype SNPs were 
available +/-500 KB on the OncoArray. Both LD plots for markers rs527510716 
(Chr 7) and rs533722308 (Chr 18) showed significant associations (P<1x10-3) for 
several genotype markers with moderate LD of the index SNP. The Kappa 
coefficient for markers rs527510716 (Chr 7) and rs533722308 (Chr 18) was 
0.911 and 0.931, respectively (Supplementary Table 9). The marker rs6602880 
(Chr 10) had a Kappa coefficient of 0.812 and was the only significant variant in 
the LD plot. The Kappa coefficient for marker rs144166867 (Chr X) was 0.665 
(Supplementary Table 9). The markers rs6602880 (Chr 10) and rs144166867 
(Chr X) are most likely false positives due to poor imputation for these regions. 
Proportion of familial risk explained 
The contribution of the known SNPs to the familial risk of PrCa, under a multiplicative 
model, was computed using the formula 
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where 0  is the observed familial risk to first degree relatives of PrCa cases
24,25, 
assumed to be 2.5, and k  is the familial relative risk due to locus k, given by: 
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where kp is the frequency of the risk allele for locus k, kk pq −=1  and kr is the 
estimated per-allele odds ratio. 
Based on the assumption of a log-additive model, we constructed a polygenic 
risk score (PRS) from the summed risk allelic dosages weighted by the per-allele 
log-odds ratios. Thus for each individual j we derived: 
 
Where: 
N : Number of SNPs  
ijg : Allele dose at SNPi for individual j 
i : Per-allele log-odds ratio of SNPi   
The risk of PrCa was estimated for the percentile of the distribution of the PRS 
(<1%, 1-10%, 10-25%, 25-75%, 75-90%, 90-99%, >99% and <10%, 10-25%, 25-
75%, 75-90%, >90%) where cumulative score thresholds were determined by the 
observed distribution among controls. We applied effect sizes and allele 
frequencies obtained from the overall meta-analysis of Europeans to estimate 
risk scores for individuals of European ancestry in the OncoArray study26. A 
standardized PRS score was calculated by dividing the observed PRS score by 
the standard deviation of the PRS score among controls. A logistic regression 
framework was used to evaluate the percentile comparisons and determine the 
risk estimate. The models were adjusted for the first seven principal components 
to account for population stratification and stratified by country. 
 
The FRR and PRS risk estimation was limited to the variants where our overall 
meta-analysis observed a statistically significant association. In total, we included 
ij
N
i
ij gScore 
=
=
1

147 PrCa index SNPs in our risk score modelling, including 85 previously 
published associations and the 62 novel findings reported here. To correct for 
potential bias in effect estimation of newly discovered variants, we implemented 
a fully Bayesian version of a weighted correction given in Zhong and Prentice, Eq 
3.427. Specifically, we place a normal prior distribution on MLE effect estimates of 
the form 𝛽𝑚~𝑁(𝛽𝐶𝑜𝑟, 𝜏
2). Here, m is the log odds ratio from the overall meta-
analysis; 𝛽𝐶𝑜𝑟  is the bias corrected estimate calculated using the expectation-
adjusted estimator from Eq 3.1 in Zhong and Prentice; and  is a pre-specified 
variance of the effect distribution reflecting the bias and is defined as 𝜏 =
|?̂?𝑚 − 𝛽𝐶𝑜𝑟|. 
 
eQTL analyses 
Genotype and gene expression data were downloaded from The Cancer 
Genome Atlas (TCGA) for 494 samples with PrCa (https://gdc-portal.nci.nih.gov). 
Quality Control (QC) was performed on both these datasets as follows: on the 
genotype, we filtered out samples with high heterozygosity (mean heterozygosity 
+/- 2 standard deviation) and missing genotypes, duplicated or related samples. 
We then performed Principal Component Analysis on the 494 samples plus 
2,506 samples from 1KGP to infer the ancestry of the TCGA samples; samples 
of non-European ancestry were removed. We also filtered out variants with 
missing call rate > 5%. For the expression data, samples from two plates had, on 
average, much higher expression values than the remaining samples, and these 
were excluded. We also filtered genes with mean expression across samples <= 
6 counts. Finally, expression values were quantile-normalized by samples and 
rank-transformed by genes. After QC we used the data from 359 samples. For 
the eQTL analysis, 35 PEER factors from the top 10,000 expressed genes were 
used as covariates, plus three genotyping PCs (which explained 18% of total 
variation). eQTL analysis was performed using FastQTL with 1,000 permutations 
over the 85 regions. We used a window of 1 Megabases (upstream/downstream) 
from the transcription start site (TSS) of each gene. 
 
Gene Set Enrichment Analyses 
The file 
Human_GOBP_AllPathways_no_GO_iea_September_01_2016_symbol.gmt 
(http://baderlab.org/EM_GeneSets), from the GeneSets database28, was used for 
all analyses. This database contains pathways from Reactome29, NCI Pathway 
Interaction Database30, GO (Gene Ontology) biological process31, HumanCyc32, 
MSigdb33, NetPath34 and Panther35.  We manually corrected several pathways 
where the PDPK1 gene was entered as PDK1. GO pathways inferred from 
electronic annotation terms were excluded. The same pathway (e.g. apoptosis) 
may be defined in two or more databases with potentially different sets of genes, 
and all versions of these duplicate/overlapping pathways were included. Pathway 
size was determined by the total number of genes in the pathway to which SNPs 
in the imputed GWAS dataset could be mapped. To provide more biologically 
meaningful results, and reduce false positives, only pathways that contained 
between 10 and 200 genes were considered.   
 
Gene information (hg19) was downloaded from the ANNOVAR36 website 
(http://www.openbioinformatics.org/annovar/). SNPs were mapped to the nearest 
gene within 500kb window; those that were further away from any gene were 
excluded. Gene significance was calculated by assigning the lowest p-value 
observed across all SNPs assigned to a gene37,38, based on the combined 
European meta-analysis (previous GWAS and OncoArray).  
 
The gene set enrichment analysis (GSEA)28 algorithm, as implemented in the 
GenGen package (http://gengen.openbioinformatics.org/en/latest/)38,39 was used 
to perform pathway analysis. Briefly, the algorithm calculates an enrichment 
score (ES) for each pathway based on a weighted Kolmogorov-Smirnov 
statistic39. To calculate the ES we performed 100 permutations and averaged the 
final score. Pathways that have most of their genes at the top of the ranked list of 
genes obtain higher ES values. Only pathways with positive ES and at least one 
gene with P<5x10-8 were retained for subsequent analysis. An enrichment map 
was created using the Enrichment Map (EM) v 2.1.0 app28 in Cytoscape v3.4040, 
applying force directed layout, weighted mode. We restricted our pathway 
analysis those with an ES≥0.50 to ensure a true positive rate > 0.20 and a false 
positive rate < 0.15.  
 
  
DATA AVAILABILITY: 
The OncoArray genotype data and relevant covariate information (i.e. ethnicity, country, 
principal components, etc.) generated during this study will be deposited into dbGAP for 
access. In total 47 of the 52 OncoArray studies encompassing nearly 90% of the 
individual samples will be available (Supplementary Table 19). The previous meta-
analysis summary results and genotype data currently12 are available in dbGAP 
(Accession #: phs001081.v1.p1). The complete meta-analysis summary associations 
statistics is publicly available at the PRACTICAL website (http://practical.icr.ac.uk/blog/). 
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